Community-acquired pneumonia is a type of pneumonia that can be spread from one person to another within the same community. The name community-acquired refers to the fact that this kind of pneumonia is more easily acquired by those living near each other, usually family or friends. Considering the geographical impact, the U.S. is exhibiting promising signs regarding the community-acquired bacterial pneumonia (CABP) treatment drugs market. This is typically due to the high prevalence of viral pneumonia and increasing demand for pneumonia therapeutics drugs in the region. Besides, with improving healthcare infrastructure in the Asia Pacific, the demand for community-acquired bacterial pneumonia (CABP) treatment drugs is likely to accelerate shortly.
Community-acquired bacterial pneumonia is one of the most common acute infections, which require hospital admission. The most dominant risk factor in CABP is age, comorbidities, and smoking. As Per the Asia Pacific Society of Respirology, the incidence of CABP was 0.81 per 1,000 individuals, which increased to 6.95 per 1,000 people year. As a result of this, the demand for CABP treatment drugs has increased massively over the years. Hence, such factors can augment the growth of the community-acquired bacterial pneumonia (CABP) treatment drugs market.
Community-acquired bacterial pneumonia is caused by bacteria that are kept in the lungs by mucus. The bacteria get into the lungs through several means, such as through an open cut in the lung tissue, coughing, or inhaling an aerosolized substance containing bacteria. Despite these advantages, inadequate penetration of antibacterial agents remains one of the key hurdles in the community-acquired bacterial pneumonia (CABP) treatment drugs market. Furthermore, antibiotic resistance in drugs is another factor impeding the growth of the community-acquired bacterial pneumonia (CABP) treatment drugs market shortly.
Community-acquired pneumonia is usually a condition that will clear up on its own after a few weeks, although in some cases may take months before the diagnosis is confirmed. This is often the case in patients who contract pneumococcal pneumonia due to streptococcus infection. Since there is a high prevalence of CABP, key players in the field of healthcare and biotechnology are focused on drug discovery. With continuous R&D activities, the advent of new and efficient drugs can provide adequate solutions for CABP treatment. Hence, such factors can stimulate the growth of the community-acquired bacterial pneumonia (CABP) treatment drugs market shortly.
Recently, in February 2021, Paratek Pharmaceuticals, Inc., a biopharmaceutical company, launched NUZYRA, a safe and once-daily oral antibiotic indicated for CABP